Biotech | August 02, 2021
Bharat Biotech gets WHO prequalification for ROTAVAC 5D
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Price band in the range of Rs 933 to Rs 954
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Subscribe To Our Newsletter & Stay Updated
